Correction to: Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells

Affiliations

• ¹ Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
• ² Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
• ³ The Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, IMRIC, Jerusalem, Israel.
• ⁴ Institute of Anatomy, Medical Faculty, University Duisburg-Essen, Essen, Germany.
• ⁵ Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. francescal@ekmd.huji.ac.il.